Disease Detail

ID DOID:1612
Name breast cancer
Definition A thoracic cancer that originates in the mammary gland.
Source DiseaseOntology.org
Alt Ids DOID:4241 DOID:1648
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant VS-5584 breast cancer sensitive detail...
TP53 P72R Daunorubicin breast cancer predicted - sensitive detail...
TP53 P72R Daunoxome breast cancer predicted - sensitive detail...
TP53 P72R Pegylated liposomal-doxorubicin breast cancer predicted - sensitive detail...
TP53 P72R Epirubicin breast cancer sensitive detail...
PIK3CA mutant Sapanisertib breast cancer sensitive detail...
ERBB2 amp Neratinib + Temsirolimus breast cancer predicted - sensitive detail...
Unknown unknown PD-0325901 breast cancer not applicable detail...
PIK3CA act mut Copanlisib breast cancer sensitive detail...
TP53 P72R TP53 Y220C Cyclophosphamide + Epirubicin breast cancer no benefit detail...
ATM dec exp Talazoparib breast cancer sensitive detail...
ERBB2 amp Dacomitinib breast cancer sensitive detail...
TP53 inact mut Adavosertib + Radiotherapy breast cancer sensitive detail...
ERBB2 amp ERBB2 T798M Trastuzumab breast cancer resistant detail...
ERBB2 T798M Buparlisib breast cancer sensitive detail...
ERBB2 T798M XL147 breast cancer sensitive detail...
ERBB2 T798M Afatinib breast cancer sensitive detail...
ERBB2 T798M Cetuximab breast cancer resistant detail...
ERBB2 T798M Cetuximab + Lapatinib breast cancer sensitive detail...
ERBB2 T798M Lapatinib + Trastuzumab breast cancer sensitive detail...
ERBB2 T798M Trastuzumab + XL147 breast cancer sensitive detail...
ERBB2 T798M CI-1040 breast cancer resistant detail...
TP53 negative Bevacizumab + Docetaxel + Doxorubicin breast cancer sensitive detail...
Unknown unknown Cyclophosphamide + Methotrexate + Vandetanib breast cancer not applicable detail...
Unknown unknown Cabozantinib breast cancer not applicable detail...
Unknown unknown Axitinib breast cancer not applicable detail...
Unknown unknown Pazopanib breast cancer not applicable detail...
TP53 inact mut AMG 900 breast cancer sensitive detail...
Unknown unknown GDC-0349 breast cancer not applicable detail...
ERBB2 over exp AV-412 breast cancer sensitive detail...
PIK3CA E545K Everolimus breast cancer sensitive detail...
PIK3CA act mut MK2206 breast cancer sensitive detail...
FGFR2 amp Dovitinib breast cancer sensitive detail...
ERBB2 D769H Lapatinib breast cancer sensitive detail...
ERBB2 D769H Neratinib breast cancer sensitive detail...
ERBB2 D769H Trastuzumab breast cancer sensitive detail...
ERBB2 D769Y Lapatinib breast cancer sensitive detail...
ERBB2 D769Y Neratinib breast cancer sensitive detail...
ERBB2 D769Y Trastuzumab breast cancer sensitive detail...
ERBB2 G309A Lapatinib breast cancer sensitive detail...
ERBB2 G309A Neratinib breast cancer sensitive detail...
ERBB2 G309A Trastuzumab breast cancer sensitive detail...
ERBB2 L755S Neratinib breast cancer sensitive detail...
ERBB2 G778_P780dup Lapatinib breast cancer resistant detail...
ERBB2 G778_P780dup Neratinib breast cancer sensitive detail...
ERBB2 G778_P780dup Trastuzumab breast cancer resistant detail...
ERBB2 R678Q Lapatinib breast cancer sensitive detail...
ERBB2 R678Q Neratinib breast cancer sensitive detail...
ERBB2 R896C Lapatinib breast cancer sensitive detail...
ERBB2 R896C Neratinib breast cancer sensitive detail...
ERBB2 R896C Trastuzumab breast cancer sensitive detail...
ERBB2 V777L Lapatinib breast cancer sensitive detail...
ERBB2 V777L Neratinib breast cancer sensitive detail...
ERBB2 V777L Trastuzumab breast cancer sensitive detail...
ERBB2 V842I Lapatinib breast cancer sensitive detail...
ERBB2 V842I Neratinib breast cancer sensitive detail...
ERBB2 V842I Trastuzumab breast cancer sensitive detail...
FBXW7 inact mut Sirolimus breast cancer sensitive detail...
PTEN mutant Sapanisertib breast cancer sensitive detail...
Unknown unknown A-1331852 + Docetaxel breast cancer not applicable detail...
PIK3CA mutant CDKN2A mutant Sapanisertib breast cancer sensitive detail...
Unknown unknown Fluoxymesterone breast cancer not applicable detail...
Unknown unknown Tamoxifen + Verrucarin A breast cancer not applicable detail...
PIK3CA mutant Capivasertib breast cancer predicted - sensitive detail...
PIK3CA mutant Pictilisib breast cancer sensitive detail...
PIK3CA mutant Temsirolimus breast cancer no benefit detail...
Unknown unknown Aldoxorubicin + ON01910 breast cancer not applicable detail...
ETV6-NTRK3 BMS-754807 breast cancer sensitive detail...
ARID1A dec exp Talazoparib breast cancer conflicting detail...
FGFR2 over exp AZ8010 breast cancer sensitive detail...
FGFR2 over exp AZD4547 breast cancer sensitive detail...
PIK3CA P539R PIK3CA H1047R PF-04691502 breast cancer sensitive detail...
PIK3CA mutant AZD8835 breast cancer sensitive detail...
PIK3CA act mut ERBB2 act mut VS-5584 breast cancer sensitive detail...
PIK3CA E545K WYE-125132 breast cancer sensitive detail...
PIK3CA mutant CH5132799 breast cancer sensitive detail...
ERBB2 amp CH5132799 breast cancer sensitive detail...
PIK3CA H1047R CH5132799 breast cancer sensitive detail...
PIK3CA E545K CH5132799 breast cancer sensitive detail...
ERBB2 amp PIK3CA C420R CH5132799 breast cancer sensitive detail...
ERBB2 amp PIK3CA N345K CH5132799 breast cancer sensitive detail...
ERBB2 amp PIK3CA H1047R CH5132799 breast cancer sensitive detail...
ERBB2 amp PIK3CA K111N CH5132799 breast cancer sensitive detail...
ERBB2 amp PIK3CA H1047R CH5132799 + Trastuzumab breast cancer sensitive detail...
ERBB2 amp PIK3CA K111N CH5132799 + Everolimus breast cancer sensitive detail...
PIK3CA E542K CH5132799 breast cancer sensitive detail...
ERBB2 amp PIK3CA E545K CH5132799 breast cancer sensitive detail...
PIK3CA mutant CUDC-907 breast cancer sensitive detail...
ERBB2 amp PIK3CA mut CUDC-907 breast cancer sensitive detail...
ERBB2 amp PIK3CA H1047R Gedatolisib breast cancer sensitive detail...
PTEN A72fs Gedatolisib breast cancer sensitive detail...
PIK3CA H1047R Gedatolisib breast cancer sensitive detail...
PIK3CA E545K Gedatolisib breast cancer sensitive detail...
FGFR2 over exp PD173074 breast cancer sensitive detail...
Unknown unknown CWP232228 breast cancer not applicable detail...
Unknown unknown Tanibirumab breast cancer not applicable detail...
FGFR1 amp Ponatinib breast cancer sensitive detail...
FGFR2 amp Ponatinib breast cancer sensitive detail...
FGFR2 wild-type Ponatinib breast cancer resistant detail...
FGFR1 wild-type Ponatinib breast cancer resistant detail...
ERBB2 over exp KU004 breast cancer sensitive detail...
Unknown unknown Gemcitabine + Trametinib breast cancer not applicable detail...
Unknown unknown Selumetinib breast cancer not applicable detail...
AKT1 E17K Capivasertib breast cancer sensitive detail...
Unknown unknown Eribulin breast cancer not applicable detail...
Unknown unknown KW-2450 breast cancer not applicable detail...
FGFR1 act mut FIIN-1 breast cancer sensitive detail...
AKT1 W80A MK2206 breast cancer resistant detail...
FGFR2 amp Debio 1347 breast cancer sensitive detail...
Unknown unknown NTRC 0066-0 breast cancer not applicable detail...
PIK3CA E542K BEZ235 breast cancer sensitive detail...
PIK3CA E545K BEZ235 breast cancer sensitive detail...
PIK3CA G1049R BEZ235 breast cancer sensitive detail...
PIK3CA H1047L BEZ235 breast cancer sensitive detail...
PIK3CA H1047R BEZ235 breast cancer sensitive detail...
PIK3CA N345K BEZ235 breast cancer sensitive detail...
PIK3CA Q546K BEZ235 breast cancer sensitive detail...
PIK3CA E542K Alpelisib breast cancer sensitive detail...
PIK3CA E545K Alpelisib breast cancer sensitive detail...
PIK3CA G1049R Alpelisib breast cancer sensitive detail...
PIK3CA H1047L Alpelisib breast cancer sensitive detail...
PIK3CA H1047R Alpelisib breast cancer sensitive detail...
PIK3CA N345K Alpelisib breast cancer sensitive detail...
PIK3CA Q546K Alpelisib breast cancer sensitive detail...
PIK3CA E542K MK2206 breast cancer sensitive detail...
PIK3CA E545K MK2206 breast cancer sensitive detail...
PIK3CA G1049R MK2206 breast cancer sensitive detail...
PIK3CA H1047L MK2206 breast cancer sensitive detail...
PIK3CA H1047R MK2206 breast cancer sensitive detail...
PIK3CA N345K MK2206 breast cancer sensitive detail...
PIK3CA Q546K MK2206 breast cancer sensitive detail...
PIK3CA E542K Lapatinib breast cancer sensitive detail...
PIK3CA E545K Lapatinib breast cancer sensitive detail...
PIK3CA G1049R Lapatinib breast cancer sensitive detail...
PIK3CA H1047L Lapatinib breast cancer sensitive detail...
PIK3CA H1047R Lapatinib breast cancer sensitive detail...
PIK3CA N345K Lapatinib breast cancer sensitive detail...
PIK3CA Q546K Lapatinib breast cancer sensitive detail...
PIK3CA E542K Neratinib breast cancer sensitive detail...
PIK3CA E545K Neratinib breast cancer sensitive detail...
PIK3CA G1049R Neratinib breast cancer sensitive detail...
PIK3CA H1047L Neratinib breast cancer sensitive detail...
PIK3CA H1047R Neratinib breast cancer sensitive detail...
PIK3CA N345K Neratinib breast cancer sensitive detail...
PIK3CA Q546K Neratinib breast cancer sensitive detail...
PIK3CA E542K Trametinib breast cancer sensitive detail...
PIK3CA E545K Trametinib breast cancer sensitive detail...
PIK3CA G1049R Trametinib breast cancer sensitive detail...
PIK3CA H1047L Trametinib breast cancer sensitive detail...
PIK3CA H1047R Trametinib breast cancer sensitive detail...
PIK3CA N345K Trametinib breast cancer sensitive detail...
PIK3CA Q546K Trametinib breast cancer sensitive detail...
ARID1A dec exp Olaparib breast cancer sensitive detail...
ARID1A dec exp Veliparib breast cancer sensitive detail...
ARID1A dec exp Rucaparib breast cancer sensitive detail...
PIK3CA act mut MK2206 + Ridaforolimus breast cancer predicted - sensitive detail...
Unknown unknown Docetaxel + MEDI5117 breast cancer not applicable detail...
Unknown unknown COG112 breast cancer not applicable detail...
ERBB2 positive Withacnistin breast cancer sensitive detail...
PTEN loss AZD6482 breast cancer sensitive detail...
PTEN loss GSK2636771 breast cancer sensitive detail...
PIK3CA mutant PTEN loss Alpelisib breast cancer resistant detail...
PIK3CA mutant PTEN loss Buparlisib breast cancer sensitive detail...
PIK3CA mutant PTEN loss Alpelisib + AZD6482 breast cancer sensitive detail...
TP53 L194F Tanespimycin + Vorinostat breast cancer sensitive detail...
TP53 L194F Tanespimycin breast cancer sensitive detail...
TP53 L194F Vorinostat breast cancer sensitive detail...
TP53 R280K Ganetespib breast cancer sensitive detail...
TP53 L194F Ganetespib breast cancer sensitive detail...
TP53 R175H Ganetespib breast cancer sensitive detail...
CDH1 R63* ERBB2 L869Q Capecitabine + Lapatinib breast cancer predicted - sensitive detail...
PIK3CA wild-type PTEN loss AZD8835 breast cancer resistant detail...
Unknown unknown F14512 breast cancer not applicable detail...
Unknown unknown TAK-960 breast cancer not applicable detail...
Unknown unknown AIM-100 breast cancer not applicable detail...
ALK wild-type Cisplatin + Dalantercept breast cancer predicted - sensitive detail...
PIK3CA E545K PKI-402 breast cancer sensitive detail...
ERBB2 act mut STK11 loss AZD8055 breast cancer sensitive detail...
RET positive Y078-DM4 breast cancer sensitive detail...
RET over exp Y078-DM1 breast cancer sensitive detail...
Unknown unknown GSK2126458 breast cancer not applicable detail...
PIK3CA mutant GSK2126458 breast cancer no benefit detail...
Unknown unknown ST7612AA1 breast cancer not applicable detail...
Unknown unknown AZD7762 + VE-821 breast cancer not applicable detail...
MET over exp Crizotinib + Rucaparib breast cancer sensitive detail...
Unknown unknown AKI603 breast cancer not applicable detail...
Unknown unknown AKI603 + Epirubicin breast cancer not applicable detail...
Unknown unknown AB61 breast cancer not applicable detail...
Unknown unknown EHop-016 breast cancer not applicable detail...
Unknown unknown Thymoquinone breast cancer not applicable detail...
PIK3CA mutant Letrozole + Taselisib breast cancer sensitive detail...
CBLC dec exp Olaparib breast cancer predicted - sensitive detail...
RAD21 wild-type N/A breast cancer not applicable detail...
Unknown unknown Carboplatin + E7449 breast cancer not applicable detail...
Unknown unknown Paclitaxel + TVB-2640 breast cancer not applicable detail...
Unknown unknown Gedatolisib breast cancer not applicable detail...
Unknown unknown Carboplatin + Veliparib breast cancer not applicable detail...
ERBB2 L755_T759del Lapatinib breast cancer resistant detail...
ERBB2 L755_T759del Gefitinib breast cancer sensitive detail...
ERBB2 L755_T759del Neratinib breast cancer sensitive detail...
ERBB2 amp Afatinib breast cancer sensitive detail...
ERBB2 L726F Lapatinib breast cancer resistant detail...
ERBB2 act mut Neratinib breast cancer sensitive detail...
NOTCH1 positive LY3039478 breast cancer sensitive detail...
NOTCH1 act mut Brontictuzumab breast cancer sensitive detail...
Unknown unknown Paclitaxel + Vantictumab breast cancer not applicable detail...
ERBB2 L726I Gefitinib breast cancer resistant detail...
Unknown unknown Pemetrexed + Sorafenib breast cancer not applicable detail...
Unknown unknown CPI-455 + Lapatinib breast cancer sensitive detail...
Unknown unknown RapaLink-1 breast cancer not applicable detail...
Unknown unknown Irinotecan + Veliparib breast cancer not applicable detail...
PIK3CA mutant Alpelisib + GSK2334470 breast cancer sensitive detail...
FGFR1 amp AZD4547 breast cancer no benefit detail...
EGFR pos ERBB2 pos S-222611 breast cancer sensitive detail...
Unknown unknown AZD8186 breast cancer not applicable detail...
Unknown unknown MLN1117 breast cancer not applicable detail...
Unknown unknown Pyr1 breast cancer not applicable detail...
ERBB2 amp Lapatinib breast cancer decreased response detail...
ERBB2 amp Torkinib breast cancer sensitive detail...
ERBB2 amp Lapatinib + Torkinib breast cancer sensitive detail...
Unknown unknown Alisertib breast cancer not applicable detail...
Unknown unknown Alisertib + Eribulin breast cancer not applicable detail...
Unknown unknown WANT3 breast cancer not applicable detail...
TP53 wild-type AMG 232 breast cancer sensitive detail...
TP53 wild-type AMG 232 + Radiotherapy breast cancer sensitive detail...
Unknown unknown GSK1904529A breast cancer not applicable detail...
FGFR2 amp FGFR2 fusion PRN1371 breast cancer sensitive detail...
PTEN mutant MS417 + Pictilisib breast cancer predicted - sensitive detail...
Unknown unknown OSI-027 breast cancer not applicable detail...
PIK3CA mutant OSI-027 breast cancer sensitive detail...
PTEN loss OSI-027 breast cancer sensitive detail...
ERBB2 L768S Trastuzumab breast cancer sensitive detail...
ERBB2 L768S Lapatinib breast cancer sensitive detail...
ERBB2 L768S Neratinib breast cancer sensitive detail...
ERBB2 V773L Trastuzumab breast cancer sensitive detail...
ERBB2 V773L Lapatinib breast cancer sensitive detail...
ERBB2 V773L Neratinib breast cancer sensitive detail...
ERBB2 K753E Trastuzumab breast cancer resistant detail...
ERBB2 K753E Lapatinib breast cancer resistant detail...
ERBB2 K753E Neratinib breast cancer sensitive detail...
AKT1 E17K BAY1125976 breast cancer sensitive detail...
PIK3CA K111N BAY1125976 breast cancer sensitive detail...
PIK3CA H1047R BAY1125976 breast cancer sensitive detail...
PIK3CA E545K BAY1125976 breast cancer sensitive detail...
PTEN L108R BAY1125976 breast cancer sensitive detail...
PTEN T319fs BAY1125976 breast cancer sensitive detail...
PIK3CA H1047R PTEN E307K BAY1125976 breast cancer sensitive detail...
PIK3CA P539R BAY1125976 breast cancer sensitive detail...
ERBB2 V659E 23814 + Tivozanib breast cancer sensitive detail...
ERBB2 positive DS-8201a breast cancer sensitive detail...
AKT1 over exp PIK3CA H1047R Alpelisib breast cancer resistant detail...
AKT1 over exp PIK3CA E545K Pictilisib breast cancer resistant detail...
PTEN C136Y Alpelisib breast cancer resistant detail...
PTEN loss Alpelisib breast cancer resistant detail...
ERBB2 amp Lapatinib + S63845 breast cancer sensitive detail...
Unknown unknown PU-H71 breast cancer not applicable detail...
FGFR2 positive BAY1187982 breast cancer sensitive detail...
FGFR2 dec exp BAY1187982 breast cancer resistant detail...
FGFR2 amp AZD4547 breast cancer sensitive detail...
FGFR1 amp FGFR2 amp E7090 breast cancer sensitive detail...
Unknown unknown SL0101 breast cancer not applicable detail...
ARID1A loss AZD8055 + MK2206 breast cancer sensitive detail...
ARID1A loss ERBB2 amp MK2206 + Trastuzumab breast cancer sensitive detail...
PIK3CA H1047R Metformin breast cancer sensitive detail...
Unknown unknown VS-5584 breast cancer not applicable detail...
TP53 wild-type SAR405838 breast cancer predicted - sensitive detail...
Unknown unknown Metformin breast cancer not applicable detail...
Unknown unknown Everolimus breast cancer not applicable detail...
Unknown unknown Everolimus + Metformin breast cancer not applicable detail...
Unknown unknown LDC1267 breast cancer not applicable detail...
FGFR1 amp BGJ398 breast cancer sensitive detail...
FGFR2 amp BGJ398 breast cancer sensitive detail...
PTEN mutant CUDC-907 breast cancer sensitive detail...
PTEN del CUDC-907 breast cancer sensitive detail...
Unknown unknown GTCpFE breast cancer not applicable detail...
Unknown unknown Afatinib + Vinorelbine breast cancer not applicable detail...
KDR over exp Sunitinib breast cancer predicted - resistant detail...
Unknown unknown Altiratinib breast cancer not applicable detail...
PIK3CA act mut BEZ235 + Venetoclax breast cancer no benefit detail...
PIK3CA H1047R PTEN loss BEZ235 + Venetoclax breast cancer no benefit detail...
PIK3CA E545K BEZ235 + Venetoclax breast cancer no benefit detail...
PIK3CA act mut BEZ235 + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA H1047R PTEN loss BEZ235 + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA E545K BEZ235 + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA E542K PTEN loss BEZ235 + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA wild-type BEZ235 + WEHI-539 breast cancer no benefit detail...
PIK3CA act mut Buparlisib + WEHI-539 breast cancer no benefit detail...
PIK3CA act mut Alpelisib + WEHI-539 breast cancer no benefit detail...
PIK3CA act mut Torin 1 + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA act mut Sapanisertib + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA act mut Vistusertib + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA wild-type A-1210477 + WEHI-539 breast cancer predicted - sensitive detail...
PIK3CA H1047R Miransertib breast cancer sensitive detail...
PIK3CA H1047R ARQ 751 breast cancer sensitive detail...
PIK3CA E545K Miransertib breast cancer sensitive detail...
PIK3CA K111N Miransertib breast cancer sensitive detail...
PIK3CA P539R PIK3CA H1047R Miransertib breast cancer sensitive detail...
PIK3CA E545K ARQ 751 breast cancer sensitive detail...
PIK3CA K111N ARQ 751 breast cancer sensitive detail...
PIK3CA P539R PIK3CA H1047R ARQ 751 breast cancer sensitive detail...
PIK3CA E542K Miransertib breast cancer sensitive detail...
ERBB2 over exp PIK3CA mut ARQ092 + Trastuzumab breast cancer sensitive detail...
ERBB2 over exp PIK3CA mut ARQ092 + Paclitaxel breast cancer sensitive detail...
PIK3CA H1047R M2698 breast cancer sensitive detail...
Unknown unknown NSC23766 breast cancer not applicable detail...
PIK3CA E545K DHM25 breast cancer sensitive detail...
PIK3CA H1047R DHM25 breast cancer sensitive detail...
PTEN L108R DHM25 breast cancer sensitive detail...
PIK3CA K111N DHM25 breast cancer sensitive detail...
PIK3CA act mut PTEN wild-type Everolimus breast cancer sensitive detail...
PIK3CA act mut PTEN wild-type Torkinib breast cancer sensitive detail...
PTEN loss Everolimus breast cancer resistant detail...
PTEN loss Torkinib breast cancer resistant detail...
PIK3CA wild-type PTEN loss Everolimus + U0126 breast cancer no benefit detail...
PIK3CA wild-type PTEN loss Everolimus + Selumetinib breast cancer no benefit detail...
PIK3CA wild-type PTEN loss Torkinib + U0126 breast cancer sensitive detail...
PIK3CA wild-type PTEN loss Selumetinib + Torkinib breast cancer sensitive detail...
Unknown unknown AJI-100 breast cancer not applicable detail...
Unknown unknown AJI-214 breast cancer not applicable detail...
ERBB2 L869R Lapatinib breast cancer resistant detail...
Unknown unknown DCBCI0901 breast cancer not applicable detail...
PIK3CA E545K SAR245409 breast cancer sensitive detail...
TP53 R175H NSC319726 breast cancer sensitive detail...
TP53 R273W NSC319726 breast cancer resistant detail...
TP53 positive Serdemetan breast cancer sensitive detail...
Unknown unknown CVX-241 breast cancer not applicable detail...
PIK3CA mutant AT13148 breast cancer sensitive detail...
Unknown unknown BGP-15 breast cancer not applicable detail...
Unknown unknown MBQ-167 breast cancer not applicable detail...
ERBB2 over exp MM-302 + Trastuzumab breast cancer sensitive detail...
ERBB2 positive ADCT-502 breast cancer sensitive detail...
Unknown unknown E7046 + Radiotherapy breast cancer not applicable detail...
Unknown unknown V158411 breast cancer not applicable detail...
ERBB2 positive XMT-1522 breast cancer sensitive detail...
TP53 mutant PK11007 breast cancer sensitive detail...
ERBB2 L869R Neratinib breast cancer sensitive detail...
ERBB2 L869R Afatinib breast cancer sensitive detail...
Unknown unknown Azacitidine + Entinostat breast cancer not applicable detail...
Unknown unknown ONC201 breast cancer not applicable detail...
PIK3CA H1047R Taselisib breast cancer sensitive detail...
ERBB2 amp Buparlisib breast cancer sensitive detail...
ERBB2 amp PIK3CA E545K Buparlisib breast cancer sensitive detail...
PIK3CA H1047R Buparlisib breast cancer sensitive detail...
ERBB2 amp LJM716 + Trastuzumab breast cancer sensitive detail...
ERBB2 amp Pertuzumab + Trastuzumab breast cancer sensitive detail...
ERBB2 amp LJM716 + Neratinib breast cancer sensitive detail...
ERBB2 amp Neratinib + Pertuzumab breast cancer sensitive detail...
MET amp TP53 del Crizotinib breast cancer sensitive detail...
Unknown unknown Barasertib breast cancer not applicable detail...
Unknown unknown JNJ-7706621 breast cancer not applicable detail...
Unknown unknown Danusertib breast cancer not applicable detail...
Unknown unknown Danusertib + Fulvestrant breast cancer not applicable detail...
Unknown unknown Alisertib + Fulvestrant breast cancer not applicable detail...
Unknown unknown Fulvestrant + JNJ-7706621 breast cancer not applicable detail...
ERBB2 mutant Neratinib breast cancer predicted - sensitive detail...
ERBB2 S310F ERBB2 V842I Neratinib breast cancer predicted - sensitive detail...
Unknown unknown H3B-6545 breast cancer not applicable detail...
PIK3CA mutant MLN1117 breast cancer predicted - sensitive detail...
Unknown unknown Hydroxyurea + NU6027 breast cancer not applicable detail...
Unknown unknown Camptothecin + NU6027 breast cancer not applicable detail...
Unknown unknown Doxorubicin + NU6027 breast cancer not applicable detail...
Unknown unknown Cisplatin + NU6027 breast cancer not applicable detail...
Unknown unknown NU6027 + Rucaparib breast cancer not applicable detail...
Unknown unknown CS-11 breast cancer not applicable detail...
FGFR2 positive Rogaratinib breast cancer predicted - sensitive detail...
Unknown unknown ISTH0047 breast cancer not applicable detail...
Unknown unknown R916562 breast cancer not applicable detail...
Unknown unknown PI-273 breast cancer not applicable detail...
HRAS mutant PI-273 breast cancer decreased response detail...
MET wild-type Glesatinib breast cancer decreased response detail...
PIK3CA mutant GDC-0077 breast cancer predicted - sensitive detail...
Unknown unknown Lucitanib breast cancer not applicable detail...
Unknown unknown Elenagen + Tamoxifen breast cancer not applicable detail...
FGFR2 amp FGFR2-GAB2 PRN1371 breast cancer sensitive detail...
AKT1 P68_C77dup Capivasertib breast cancer sensitive detail...
PIK3CA H450_P458del Alpelisib breast cancer sensitive detail...
Unknown unknown ICEC0942 breast cancer sensitive detail...
Unknown unknown XL388 breast cancer not applicable detail...
Unknown unknown Triolimus breast cancer not applicable detail...
ERBB2 positive MI130004 breast cancer sensitive detail...
FGFR2 amp Derazantinib breast cancer sensitive detail...
Unknown unknown Vinflunine breast cancer not applicable detail...
PIK3CA E39K Buparlisib breast cancer resistant detail...
PIK3CA N345I Buparlisib breast cancer resistant detail...
PIK3CA E453K Buparlisib breast cancer resistant detail...
PIK3CA E542K Buparlisib breast cancer resistant detail...
PIK3CA E545K Buparlisib breast cancer resistant detail...
PIK3CA G1049R Buparlisib breast cancer resistant detail...
Unknown unknown SKLB-23bb breast cancer not applicable detail...
ERBB2 positive SYD985 breast cancer predicted - sensitive detail...
Unknown unknown GA001 breast cancer not applicable detail...
Unknown unknown INCB081776 + unspecified PD-L1 antibody breast cancer not applicable detail...
ERBB2 positive ARX-788 breast cancer sensitive detail...
ERBB2 positive Ado-trastuzumab emtansine + Tucatinib breast cancer sensitive detail...
Unknown unknown Imatinib breast cancer no benefit detail...
KIT positive Imatinib + Letrozole breast cancer predicted - sensitive detail...
BRAF L514V Dabrafenib breast cancer resistant detail...
Unknown unknown MC180295 breast cancer not applicable detail...
RB1 positive Paclitaxel + Palbociclib breast cancer predicted - sensitive detail...
Unknown unknown MBG453 breast cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00194714 Phase Ib/II HER2 Vaccine Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Active, not recruiting
NCT00378638 Phase II Bevacizumab Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer Unknown status
NCT00570323 Phase II Anastrozole + Fulvestrant Anastrozole Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer Active, not recruiting
NCT00618657 Phase II Carboplatin + Nab-paclitaxel + Trastuzumab Bevacizumab + Carboplatin + Nab-paclitaxel Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Active, not recruiting
NCT00651976 Phase I Letrozole Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery Terminated
NCT00719875 Phase Ib/II Vorinostat HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer Completed
NCT00733408 Phase II Bevacizumab + Erlotinib + Nab-paclitaxel Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer Completed
NCT00740805 Phase I Aldoxorubicin + Cyclophosphamide + Veliparib Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Active, not recruiting
NCT00892736 Phase I Veliparib Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy Completed
NCT00912340 Phase II Everolimus Trastuzumab Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer Completed
NCT00968968 Phase III Trastuzumab Lapatinib + Trastuzumab Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone Terminated
NCT00978250 Phase II 5-Fluoro-2-deoxycytidine + Tetrahydrouridine A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Completed
NCT01008150 Phase II Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer Completed
NCT01035099 Phase I Letrozole RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF Active, not recruiting
NCT01037790 Phase II Palbociclib PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER Recruiting
NCT01042379 Phase II Trebananib Pertuzumab + Trastuzumab Ganitumab Cyclophosphamide + Doxorubicin + Paclitaxel MK2206 + Trastuzumab Trastuzumab + Trebananib Ado-trastuzumab emtansine + Pertuzumab I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Recruiting
NCT01106898 Phase II Cyclophosphamide + Paclitaxel Trastuzumab Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery Completed
NCT01148849 Phase I MGAH22 Safety Study of MGAH22 in HER2-positive Carcinomas Active, not recruiting
NCT01194869 Phase II Cisplatin + Paclitaxel + Sorafenib Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer Terminated
NCT01216176 Phase Ib/II Anastrozole Saracatinib A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Completed
NCT01262027 Phase II Dovitinib TKI258 for Metastatic Inflammatory Breast Cancer Patients Unknown status
NCT01275677 Phase III Cyclophosphamide + Doxorubicin + Paclitaxel + Trastuzumab Cyclophosphamide + Docetaxel Cyclophosphamide + Docetaxel + Trastuzumab Cyclophosphamide + Doxorubicin + Paclitaxel Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Active, not recruiting
NCT01281150 Phase I Veliparib Paclitaxel Carboplatin Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed
NCT01283789 Phase II Everolimus + Lapatinib Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer Unknown status
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed
NCT01293032 Phase I Tamoxifen Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Completed
NCT01300962 Phase I Buparlisib + Capecitabine + Lapatinib Buparlisib + Capecitabine + Trastuzumab Buparlisib + Capecitabine Alpelisib + Capecitabine Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer Active, not recruiting
NCT01302379 Phase I Metformin Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors Unknown status
NCT01310231 Phase II Metformin A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer Completed
NCT01320592 Phase I Palbociclib Paclitaxel PD0332991/Paclitaxel in Advanced Breast Cancer Active, not recruiting
NCT01325441 Phase Ib/II Napabucasin + Paclitaxel A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting
NCT01340300 Phase II Metformin Exercise and Metformin in Colorectal and Breast Cancer Survivors Completed
NCT01358877 Phase III Pertuzumab Trastuzumab A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer Active, not recruiting
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting
NCT01384253 Phase I 212Pb-TCMC-Trastuzumab + Trastuzumab Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy Completed
NCT01386580 Phase Ib/II 2B3-101 2B3-101 + Trastuzumab An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. Completed
NCT01401959 Phase II Eribulin Eribulin + Trastuzumab Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Completed
NCT01407562 Phase I Carboplatin Paclitaxel Pazopanib Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors Active, not recruiting
NCT01480583 Phase II Trastuzumab GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases Completed
NCT01501487 FDA approved Cyclophosphamide + Docetaxel + Doxorubicin Cyclophosphamide + Epirubicin + Fluorouracil Paclitaxel Pegfilgrastim Cyclophosphamide + Docetaxel Cyclophosphamide + Doxorubicin Carboplatin + Docetaxel + Trastuzumab Docetaxel + Pertuzumab + Trastuzumab MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Completed
NCT01506609 Phase II Temozolomide + Veliparib Carboplatin + Etoposide + Veliparib Carboplatin + Paclitaxel The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer Active, not recruiting
NCT01517802 Phase III Abiraterone A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate Active, not recruiting
NCT01525589 Phase II Lurbinectedin A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer Completed
NCT01532960 Phase I Poly ICLC Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41) Terminated
NCT01545648 Phase II Denosumab Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer Active, not recruiting
NCT01562873 Ruxolitinib Ruxolitinib in Patients With Breast Cancer Terminated
NCT01570036 Phase II E75 Sargramostim Trastuzumab Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Completed
NCT01576666 Phase Ib/II Buparlisib + Sonidegib Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Completed
NCT01596751 Phase Ib/II Eribulin Pexidartinib Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer Active, not recruiting
NCT01597388 Phase I Fulvestrant + Vistusertib AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer Active, not recruiting
NCT01625286 Phase Ib/II Capivasertib + Paclitaxel Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients Active, not recruiting
NCT01640665 Phase I Capecitabine + Sorafenib Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors Completed
NCT01650506 Phase I Erlotinib + Metformin Study of Erlotinib and Metformin in Triple Negative Breast Cancer Completed
NCT01656538 Phase II Reolysin Paclitaxel A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer Completed
NCT01669343 Phase I Letrozole Aromatase Inhibitor Host Factors Study Unknown status
NCT01676753 Phase I Dinaciclib + Pembrolizumab Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer Recruiting
NCT01723774 Phase II Palbociclib Anastrozole Goserelin PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Recruiting
NCT01730833 Phase II Paclitaxel + Pertuzumab + Trastuzumab Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer Active, not recruiting
NCT01750073 Phase II Doxorubicin Trastuzumab Cyclophosphamide + Paclitaxel Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer Recruiting
NCT01831089 Phase I Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed
NCT01837602 Phase I cMet CAR RNA T Cells Targeting Breast Cancer Completed
NCT01847001 Phase II Propranolol Paclitaxel + Pertuzumab + Trastuzumab Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Active, not recruiting
NCT01853306 Phase I Veliparib A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors Completed
NCT01862900 Phase Ib/II MEDI6469 Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions Completed
NCT01868503 Phase II Lapatinib Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer Terminated
NCT01870505 Phase I Alpelisib + Exemestane Alpelisib + Letrozole BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer Active, not recruiting
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Recruiting
NCT01934335 Phase I Vandetanib Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer Terminated
NCT01966445 Phase I GSK2849330 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors Completed
NCT01980823 Phase I Atorvastatin + Metformin Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Recruiting
NCT01989546 Phase Ib/II Talazoparib Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Recruiting
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Recruiting
NCT01990352 Phase II Pegylated liposomal-doxorubicin Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy Active, not recruiting
NCT02000622 Phase III Olaparib Vinorelbine Eribulin Capecitabine Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD) Active, not recruiting
NCT02007512 Phase II Enzalutamide + Exemestane Exemestane Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer Active, not recruiting
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02025803 Phase I Capecitabine + TAS-114 A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors Completed
NCT02040857 Phase II Exemestane Palbociclib Tamoxifen Letrozole Anastrozole Palbociclib + Endocrine Therapy for HR + BrCa Active, not recruiting
NCT02041429 Phase Ib/II Paclitaxel + Ruxolitinib Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca Active, not recruiting
NCT02046421 Phase I Mifepristone Carboplatin + Gemcitabine Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Completed
NCT02047747 Phase II Dacomitinib A Phase II Study of Dacomitinib in Progressive Brain Metastases Terminated
NCT02048059 Phase II GRN1005 ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases Completed
NCT02051751 Phase I Alpelisib + Paclitaxel A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Completed
NCT02077933 Phase I Alpelisib + Everolimus Alpelisib + Everolimus + Exemestane Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors Completed
NCT02122861 Phase I ID-LV305 A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 Completed
NCT02124148 Phase I Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Active, not recruiting
NCT02168777 Phase Ib/II Refametinib + Regorafenib Refametinib Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer Terminated
NCT02202746 Phase II Lucitanib A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer Completed
NCT02203513 Phase II Prexasertib A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Recruiting
NCT02230319 Phase II Paclitaxel Prevention of Paclitaxel Neuropathy With Cryotherapy Unknown status
NCT02260531 Phase II Cabozantinib Trastuzumab Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases Active, not recruiting
NCT02265536 Phase I LY3022855 A Study of LY3022855 In Participants With Breast or Prostate Cancer Completed
NCT02303990 Phase I Pembrolizumab RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers Active, not recruiting
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Active, not recruiting
NCT02310464 Phase I OBI-821 + OBI-833 Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects Recruiting
NCT02314156 Phase II Telapristone Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy Active, not recruiting
NCT02340221 Phase III Fulvestrant Taselisib SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy Active, not recruiting
NCT02366130 Phase II Tamoxifen Denosumab + Radium Ra 223 dichloride Fulvestrant Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer Active, not recruiting
NCT02379585 Phase Ib/II Cyclophosphamide + Doxorubicin + Paclitaxel Docetaxel + Pertuzumab + Trastuzumab Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer Terminated
NCT02384239 Phase II Fulvestrant + Palbociclib Palbociclib + Tamoxifen A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer Active, not recruiting
NCT02391480 Phase I ABBV-075 A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer Active, not recruiting
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib INCMGA00012 + Pemigatinib Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting
NCT02393794 Phase Ib/II Cisplatin + Nivolumab + Romidepsin Cisplatin + Romidepsin Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Recruiting
NCT02414269 Phase I Cyclophosphamide + iCasp9M28z T cells iCasp9M28z T cells Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin Recruiting
NCT02540330 Phase II Fulvestrant PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy Recruiting
NCT02563925 Phase I Tremelimumab Brain Irradiation and Tremelimumab in Metastatic Breast Cancer Active, not recruiting
NCT02564900 Phase I DS-8201a Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors Active, not recruiting
NCT02576665 Phase I Toca 511 + Toca FC A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) Active, not recruiting
NCT02595905 Phase II Cisplatin Cisplatin + Veliparib Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases Active, not recruiting
NCT02599363 Phase I Paclitaxel + Ribociclib A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer Recruiting
NCT02605486 Phase Ib/II Bicalutamide + Palbociclib Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) Recruiting
NCT02623972 Phase II Cyclophosphamide + Doxorubicin + Eribulin A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Recruiting
NCT02639026 Phase I Durvalumab + Tremelimumab Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers Recruiting
NCT02640508 Phase II Eribulin + Lenvatinib Eribulin and Lenvatinib in Advanced Solid Tumors Active, not recruiting
NCT02643303 Phase Ib/II Durvalumab + Poly ICLC Tremelimumab A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting
NCT02646319 Phase I Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed
NCT02650635 Phase I Cyclophosphamide + Motolimod + Pegfilgrastim TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated
NCT02673398 Phase II Neratinib Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer Active, not recruiting
NCT02721433 FDA approved Denosumab + pamidronate + Zoledronic acid 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA) Active, not recruiting
NCT02725541 Phase II Ado-trastuzumab emtansine Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer Withdrawn
NCT02734004 Phase Ib/II Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) Recruiting
NCT02746328 Phase II enobosarm Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass Completed
NCT02751528 ETBX-021 QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer Recruiting
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02874430 Phase II Doxycycline + Metformin Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting
NCT02900469 Phase 0 Denosumab Safety Study of Denosumab to Treat Breast Cancer Recruiting
NCT02926690 Phase I OTS167 Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer Recruiting
NCT02939274 Phase II Verteporfin An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer Recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Recruiting
NCT02965885 Phase I TAS-116 A Study of TAS-116 in Patients With Solid Tumors Completed
NCT02980341 Phase Ib/II U3-1402 Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer Recruiting
NCT02985658 Phase I Cisplatin Veliparib Vinorelbine Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer Available
NCT02999477 Phase I Pembrolizumab Nab-paclitaxel A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer Recruiting
NCT03006172 Phase I GDC-0077 + Letrozole + Palbociclib GDC-0077 Fulvestrant + GDC-0077 GDC-0077 + Letrozole To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer Recruiting
NCT03025035 Phase II Pembrolizumab Pembrolizumab in Advanced BRCA-mutated Breast Cancer Recruiting
NCT03032107 Phase I Ado-trastuzumab emtansine + Pembrolizumab A Study Of Pembrolizumab In Combination With Trastuzumab-DM1 Recruiting
NCT03032406 Phase II Everolimus + Hydroxychloroquine Everolimus Hydroxychloroquine CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer Recruiting
NCT03044730 Phase II Capecitabine + Pembrolizumab Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT03065387 Phase I Everolimus + Neratinib Neratinib + Palbociclib Neratinib + Trametinib Study of the Pan-ERBB InhibStudy of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, HER3/4 Mutation or KRAS Mutation Recruiting
NCT03066947 Phase Ib/II Cyclophosphamide + Interferon alpha-2b + SV-BR-1-GM SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Completed
NCT03088527 Phase I RAD140 A Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer Recruiting
NCT03095352 Phase II Carboplatin + Pembrolizumab A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Recruiting
NCT03099174 Phase I Abemaciclib + Xentuzumab Abemaciclib + Letrozole + Xentuzumab Abemaciclib + Anastrozole + Xentuzumab Abemaciclib + Fulvestrant + Xentuzumab This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer. Recruiting
NCT03101748 Phase Ib/II Neratinib + Paclitaxel + Pertuzumab + Trastuzumab Cyclophosphamide + Doxorubicin + Neratinib + Paclitaxel 3HT With Taxol for Metastatic Breast Cancer Recruiting
NCT03102606 Phase II Plinabulin Pegfilgrastim Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1) Active, not recruiting
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03154281 Phase I Everolimus + Niraparib Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast Recruiting
NCT03179904 Phase II Paclitaxel + Trastuzumab + TVB-2640 FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer Recruiting
NCT03199586 Phase I NP-G2-044 Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) Recruiting
NCT03207529 Phase I Alpelisib + Enzalutamide Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer Recruiting
NCT03219476 Phase II Anastrozole Letrozole Tamoxifen Exemestane Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HERNegative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance Recruiting
NCT03237572 Phase I Pembrolizumab Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48) Recruiting
NCT03248492 Phase II DS-8201a DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Active, not recruiting
NCT03272334 Phase Ib/II HER2 BATs + Pembrolizumab Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47) Recruiting
NCT03292536 Phase I Merestinib Merestinib on Bone Metastases in Subjects With Breast Cancer Recruiting
NCT03317405 Phase I Z-endoxifen HCl Z-Endoxifen Hydrochloride in Treating Patients With Stage 0-III Breast Cancer Undergoing Surgery Recruiting
NCT03328026 Phase Ib/II Cyclophosphamide + Interferon alpha-2b + Ipilimumab + SV-BR-1-GM Cyclophosphamide + Interferon alpha-2b + Pembrolizumab + SV-BR-1-GM Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03342417 Phase II Ipilimumab + Nivolumab Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Terminated
NCT03344965 Phase II Olaparib Olaparib In Metastatic Breast Cancer Recruiting
NCT03363776 Phase Ib/II BMS-986277 BMS-986277 + Nivolumab An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers Active, not recruiting
NCT03394027 Phase II ONC201 ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma Recruiting
NCT03396211 Phase I Apatinib + Nivolumab Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer Recruiting
NCT03400254 Phase Ib/II Gedatolisib + Hydroxychloroquine Hydroxychloroquine A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") (GLACIER) Recruiting
NCT03409458 Phase Ib/II Avelumab + PT-112 A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab (PAVE-1) Recruiting
NCT03410927 Phase Ib/II TAS0728 A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Active, not recruiting
NCT03448042 Phase I BTRC 4017A A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers Recruiting
NCT03449238 Phase Ib/II Pembrolizumab Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients Recruiting
NCT03476681 Phase I NEO-201 QUILT-3.017: Study of NEO-201 in Solid Tumors Recruiting
NCT03523572 Phase I DS-8201a + Nivolumab Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer Recruiting
NCT03565445 Phase I ASP1948 + Nivolumab ASP1948 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors Recruiting
NCT03596372 Phase I BAY1834942 Study of BAY1834942 in Patients With Solid Tumors Recruiting
NCT03602079 Phase Ib/II A166 Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Recruiting
NCT03608020 Phase Ib/II BMX-001 A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy Recruiting
NCT03628677 Phase I AB154 AB154 + GLS-010 A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies Recruiting
NCT03629756 Phase I AB928 + GLS-010 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies Recruiting
NCT03632941 Phase II Pembrolizumab AVX901 + Pembrolizumab AVX901 A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer Recruiting
NCT03641755 Phase Ib/II Olaparib + sapacitabine A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer Recruiting
NCT03661424 Phase I HER2 BATs BATs in Patients With Breast Cancer and Leptomeningeal Metastases Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03691493 Phase II Letrozole + Palbociclib Palbociclib + Tamoxifen Fulvestrant + Palbociclib Anastrozole + Palbociclib Exemestane + Palbociclib Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE) Recruiting
NCT03717415 Phase Ib/II Carboplatin + Rebastinib A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors Recruiting
NCT03719768 Phase I Avelumab Avelumab With Radiotherapy in Patients With Leptomeningeal Disease Recruiting
NCT03734029 Phase III DS-8201a Nab-paclitaxel Capecitabine Paclitaxel Gemcitabine Eribulin DS-8201a Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] Recruiting
NCT03742245 Phase I Olaparib + Vorinostat Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer Not yet recruiting
NCT03763604 Expanded access Abemaciclib Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer Available
NCT03786094 Phase III Eribulin Eribulin + POL6326 Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer Recruiting
NCT03789097 Phase Ib/II CDX-301 + Pembrolizumab + Poly ICLC Vaccination With Flt3L, Radiation, and Poly-ICLC Recruiting
NCT03796273 Phase I Ketoconazole Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases Recruiting
NCT03807765 Phase I Nivolumab Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases Recruiting
NCT03820141 Phase II Durvalumab + Pertuzumab + Trastuzumab Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (DTP) Not yet recruiting
NCT03878524 Phase I Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) Not yet recruiting
NCT03952325 Phase II Pembrolizumab + Tesetaxel Nivolumab + Tesetaxel Tesetaxel Atezolizumab + Tesetaxel Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO) Recruiting
NCT03955640 Phase I Olaparib Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences Recruiting
NCT03964532 Phase Ib/II Talazoparib Avelumab + Talazoparib TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer Recruiting
NCT03970382 Phase I NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Recruiting
NCT03982004 Phase I Imiquimod + Pembrolizumab + Sargramostim Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer Not yet recruiting
NCT04009044 Phase II Afimoxifene Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast Not yet recruiting